Ghiaseddin, A., Reardon, D. A., Massey, W., Mannerino, A., Lipp, E. S., Herndon, J. E., … Peters, K. B. (2015). Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. In Journal of Clinical Oncology (Vol. 33, pp. 2034–2034). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.2034

Ghiaseddin, Ashley, David A. Reardon, Woody Massey, Alexandra Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” In Journal of Clinical Oncology, 33:2034–2034. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2034.

Ghiaseddin A, Reardon DA, Massey W, Mannerino A, Lipp ES, Herndon JE, et al. Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2034–2034.

Ghiaseddin, Ashley, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 2034–2034. Crossref, doi:10.1200/jco.2015.33.15_suppl.2034.

Ghiaseddin A, Reardon DA, Massey W, Mannerino A, Lipp ES, Herndon JE, McSherry F, Desjardins A, Randazzo DM, Vlahovic G, Friedman HS, Peters KB. Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2034–2034.